|
| |
|
CellXplore is a new, privately held biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.
The company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.
CellXplore’s platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer’s disease, Parkinson’s disease and inflammatory diseases. |
| |
|
|
| |
|
back to top |
| |
|
|
 |
|
Snowdon, Inc., is a drug discovery and development company that is focused on three major therapeutic areas with substantial market potential—cancer, acute and chronic pain and infectious diseases. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicine.
Snowdon's proven discovery platform is built for speed, economy and maximum success rate. They employ a battery of proprietary computational tools to rapidly identify high-value molecules from their fast in silico library of vendor-available compounds, which can then be procured for initial biological proof of concept evaluation studies.
Visit Snowdon's web site: www.snowdonpharma.com |
| |
|
|
| |
|
back to top |
| |
|
|
|
